Novartis won't take 'hint' as German HTA says Gilenya offers little additional benefit
This article was originally published in Scrip
Executive Summary
Novartis's oral MS drug Gilenya (fingolimod) appears to have been 'damned with faint praise' as the German reimbursement process concluded that the drug only demonstrated "a hint of benefit", in comparison with interferon beta treatment and no benefit compared to Teva's Copaxone. Novartis put this down to "teething troubles" in the new German system and hopes that it will be remedied subsequently
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.